Status:
TERMINATED
Fucidin® Cream in the Treatment of Impetigo
Lead Sponsor:
LEO Pharma
Conditions:
Impetigo
Eligibility:
All Genders
2-11 years
Phase:
PHASE4
Brief Summary
To investigate the clinical and bacteriological efficacy of Fucidin® cream in the treatment of impetigo in paediatric patients. To assess the validity of in vitro susceptibility-testing of S. aureus ...
Eligibility Criteria
Inclusion
- Patients with a clinical diagnosis of impetigo,
- Patients aged 2-11 years,
- Patients of either sex,
- Patients whose parent(s) has(ve) provided written consent, AND
- Patients with a severity score of 1 for at least one of the following signs: pustules/infected bullae, erythema and infiltration/induration.
Exclusion
- Patients with other active inflammatory dermatitis at the area of impetigo,
- Patients with a temperature above 38.5 C rectally (or equivalent), OR
- Patients who have been administered topical or systemic Fucidin® or other antibacterial agents within the previous 4 weeks.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00986856
Start Date
May 1 2004
End Date
March 1 2005
Last Update
March 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Internal Medicin, Haukeland University Hospital
Bergen, Norway, 5021
2
Vårdcentrum Kungshöjd
Gothenburg, Sweden, 411 19